ClinicalTrials.gg
RecruitingNCT06203847REVIVESUpdated Nov 19, 2025

The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCA

An interventional study of Combination group and Standard group in Cardiac Arrest, Out-Of-Hospital Cardiac Arrest and Emergency Medical Services, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Primary conditionOut-of-Hospital Cardiac ArrestRegistry: Heart ArrestReclassifiedWhy we changed it
Registry
Heart Arrest — the first condition term the registry derived for this study.
ClinicalTrials.gg
Out-of-Hospital Cardiac Arrest
Why
  1. The study's listed conditions name Out-of-Hospital Cardiac Arrest, a narrower term within Heart Arrest.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,344
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital — 6 open to participants now, 7 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · National Taiwan University Hospital.

Started
2024
with 1 other
No phase
8 of 15
2 open now
Registered
11th of 15
by date

Among the 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital, this one is one of 2 that started in 2024, is one of 8 with no phase, and was the 11th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

6 of the 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Out-of-Hospital Cardiac Arrest by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This project is a randomized controlled clinical research design, The hypothesis P-I-C-O of the study is: For adult patients in the Taipei City and New Taipei City communities who have suffered sudden non-traumatic death and have been resuscitated by advanced paramedics, the intervention group that receives combined drug treatment (epinephrine, vasopressin, methylprednisolone) has a better rate of sustained recovery of spontaneous circulation (ROSC) (primary outcome) and long-term survival status (secondary outcomes) compared to the control group that receives single drug treatment (epinephrine).

Read the detailed description

The global and Taiwanese survival rates for patients following an out-of-hospital cardiac arrest (OHCA) are less than 10%. The emergency medical system (EMS) plays a crucial role in patient outcomes after OHCA, providing prehospital cardiopulmonary resuscitation, defibrillation, and medication. Among these medications, the combination of epinephrine, vasopressin, and methylprednisolone holds the most potential to improve patient survival rates following OHCA.

This study aims to compare the effect of standard epinephrine therapy with a combination of epinephrine, vasopressin, and methylprednisolone administered to OHCA patients. This comparison will be made through a randomized clinical trial (RCT) within the EMS of Taipei City and New Taipei City.

Throughout the research plan, we will conduct a prehospital RCT to answer the following question (in P-I-C-O format): Will adult non-traumatic OHCA patients resuscitated by paramedics in a prehospital setting have a better chance of sustained recovery of spontaneous circulation (primary outcome), and improved survival status (secondary outcomes), if they receive combination therapy (i.e., standard doses of epinephrine, 20U of vasopressin after each dose of epinephrine up to a maximum of 80U, and one dose of 40mg methylprednisolone after the first dose of epinephrine) compared to those who receive standard doses of epinephrine? We estimate a sample size of 1,344 OHCA patients to detect a difference in the primary outcome. Based on the background data from the EMS regions under study, we expect the enrollment to take approximately 30 months to complete.

This study is referred to as the "OHCA-REVIVES" trial, which stands for A randomized clinical trial of patient outcomes following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid. The anticipated results from the "OHCA-REVIVES trial" will help determine the optimal strategy for prehospital medication, and will undoubtedly have a significant impact on resuscitation science. Through these efforts, we aim to improve the outcomes of OHCA patients.

03

Conditions studied

  • Cardiac Arrest
  • Out-Of-Hospital Cardiac Arrest
  • Emergency Medical Services

Browse trials for

Keywords

  • Out-Of-Hospital Cardiac Arrest
  • Emergency Medical Services
  • Corticosteroid
  • Epinephrine
  • Vasopressin
04

In context

Out-of-Hospital Cardiac Arrest Reclassified

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

This study's planned enrollment of 1,344 is above the median of 218 across 179 interventional studies indexed under Out-of-Hospital Cardiac Arrest.

Browse Out-of-Hospital Cardiac Arrest studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Compared within Out-of-Hospital Cardiac Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Arrest. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged >= 18 )
  • Out-of-hospital cardiac arrest in the studied regions
  • Treated by paramedics authorized and capable of giving prehospital medication

Exclusion criteria

Exclusion Criteria:

  • OHCA with traumatic etiology
  • Obvious signs of death like decapitation, rigor mortis, livor mortis, decomposition, etc.
  • DNR (Do Not Resuscitation) or termination of resuscitation requested by the family
  • Patients with known or suspected pregnancy
  • No vascular access was established before hospital arrival
  • ROSC before the administrated medication
  • No patient contact (cancelled ambulance call or the patient was transported to the hospital before the arrival of trial-trained paramedics)
  • Received epinephrine prior to the arrival of trial-trained paramedics
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,344 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Combined drug treatment: includes epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes, vasopressin (Pitressin® 20Unints/vial) every 3-5 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial). The method of administration is as follows: after the first administration of epinephrine (Adrenaline® 1mg/vial) to patients with cardiac arrest before hospital arrival, vasopressin (Pitressin® 20Unints/vial) and methylprednisolone (Solu-Medrol® 40mg/vial) are given simultaneously; thereafter, every 3-5 minutes, 1 mg (1 dose) of (Adrenaline® 1mg/vial) is given, along with 20 Units (1 dose) of vasopressin (Pitressin® 20Unints/vial) up to a maximum of 4 doses (a total of 80 Units) of vasopressin can be given before hospital arrival.

    Drug: Combination group

  • Active comparator
    Control group

    Standard drug treatment: epinephrine (Adrenaline® 1mg/vial). According to international resuscitation guidelines ( Advanced Cardiac Life Support, ACLS), patients with cardiac arrest before hospital arrival are given 1 mg (1 dose) of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes.

    Drug: Standard group

Interventions

  • DrugCombination group

    Combination of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes, vasopressin (Pitressin® 20Unints/vial) every 3-5 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)

  • DrugStandard group

    standard doses of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes

07

What researchers measure

Primary outcomes

  1. Rate of sustained return of spontaneous circulation (ROSC)

    Return of spontaneous circulation (ROSC) is the restart of a sustained heart rhythm measured by pulsation and vital signs that permeate the body after a cardiac arrest. Sustained ROSC ≥ 2 hours has been used as an surrogate to survival to hospital admission in many overcrowded emergency departments (ED).

    Time frame: estimated 2 hours

Secondary outcomes

  1. Rate of prehospital return of spontaneous circulation (ROSC)

    presence of ROSC prior to arrival at emergency department (ED)

    Time frame: estimated 1 hour

  2. Rate of survival to hospital discharge

    survival to hospital admission, and without in-hospital death

    Time frame: estimated 30 days

  3. Rate of survival with favorable neurologic status

    Good neurologic status (defined as Cerebral-Performance Category (CPC) score 1 and 2) at hospital discharge

    Time frame: estimated 30 days

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Ko YC, Lin YY, Yang WS, Tseng YT, Huang TJ, Lai CT, Huang SY, Hsieh CM, Wang PL, Chen HH, Chen KY, Sun JT, Chang CH, Lu TP, Ma MH, Chiang WC. Vasopressin, steroids, and epinephrine in out-of-hospital cardiac arrest - a protocol for a randomized controlled trial (OHCA REVIVES trial). Resusc Plus. 2025 Nov 18;27:101163. doi: 10.1016/j.resplu.2025.101163. eCollection 2026 Jan. PubMed 41399685 ↗

Individual participant data

Plan to share: Yes — Upon completion of the study, the sharing of Individual Participant Data (IPD) will be made available in accordance with local privacy protection laws.

Supporting information: Study protocol

Time frame: Upon completion of the study, estimated at the end of 2026, the sharing of Individual Participant Data (IPD) will be made available following local privacy protection laws.

Access criteria: reasonable request to the corresponding authors.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

Of 93 non-industry interventional studies with no phase under Out-of-Hospital Cardiac Arrest, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 95 studies reached it within 34 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 12, 2024
StartActual
Jul 16, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06203847
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Jul 16, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

WEN CHU CHIANG, PhD
Contact
drchiang.tw@gmail.com
+886 926131851
WEN CHU CHIANG, Phd
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion